Nvidia's post-governance shock era kicks off with a massive top-line earnings beat, but a deepening negative gamma regime and hawkish Fedspeak are suppressing the broader market's ability to bounce.
Yesterday we tracked the $108.99 billion Q3 revenue consensus and heavy options implied move; Nvidia delivered a massive top-line beat of $115.84 billion with adjusted EPS of $2.68. The company issued Q4 revenue guidance of $130 billion and raised its fiscal 2028 growth outlook to 75%. Data center revenue reached $107.6 billion, backed by multi-year supply commitments surging to $390 billion and a $150 billion buyback authorization expansion. Interim CEO Colette Kress confirmed licensed Hopper shipments to China have ceased, while Chair Harvey Jones stated the board will not reinstate former CEO Jensen Huang.
Why it matters
Nvidia's ability to comfortably clear elevated top-line figures alleviates immediate fears of an AI infrastructure capex cliff following recent executive turmoil and export curb announcements. The jump in supply commitments to $390B confirms durable multi-year procurement visibility among hyperscalers, providing an immediate fundamental anchor for the broader tech sector. For swing traders, the post-earnings gap and high-volume hold set up clear continuation triggers across semiconductor and neocloud supply-chain proxies.
Target Corporation (TGT) reported Q3 adjusted EPS of $2.65 and revenue of $27.1 billion on Wednesday, November 18, beating Street estimates behind a 5.6% comparable sales gain and 5.0% traffic growth. Management raised full-year sales growth to ~6% and EPS guidance to $10.65-$11.40, incorporating $2.14 in cumulative tariff refund benefits. Despite the top and bottom line double-beat, shares dipped in premarket trading as investors parsed the non-operating nature of the tariff benefit.
Why it matters
Target's robust 5.0% foot-traffic growth demonstrates resilient core consumer demand, but the premarket weakness highlights market sensitivity to non-operational earnings boosts. This initial post-earnings fade in a fundamental beat candidate creates a potential gap-fill or mean-reversion setup once regular-session volume absorbs the headline mix. Swing traders should monitor key technical support zones during the opening drive for signs of institutional dip-buying.
Sellas Life Sciences (SLS) reported on Tuesday, November 17, that its randomized Phase 3 REGAL trial evaluating galinpepimut-S in acute myeloid leukemia met its primary endpoint, demonstrating median overall survival of 24.0 months versus 14.7 months for the control arm. The stock opened up 222.69% and generated $2.6 billion in estimated turnover as retail and institutional volume flooded the tape.
Why it matters
A 9.3-month median survival advantage in a hard-to-treat oncology indication provides clear clinical differentiation and validates the platform's commercial viability. The sheer volume turnover ($2.6B) transforms the small-cap ticker into a high-liquidity vehicle for day and swing operators. Traders should watch whether intraday price action holds VWAP off the initial gap or if heavy profit-taking forces a classic post-catalyst gap fill.
Nebius Group (NBIS) stock bounced 8.4% to 10% in extended-hours trading following Nvidia's Q3 results and disclosure of $32 billion in total neocloud commitments. The bounce follows a sharp 25% two-day drawdown for Nebius sparked by its November 12 release, where capacity delays narrowed full-year guidance despite Q3 revenue surging 571% YoY to $980.8 million. Peer neoclouds CoreWeave and Iren also jumped 7% to 9% after hours.
Why it matters
This setup illustrates how primary vendor earnings prints can trigger sharp mean-reversion bounces in heavily shorted, oversold derivative names. Nvidia's explicit validation of neocloud capacity demand counters recent market fears regarding GPU rental oversupply and financing dilution. Swing traders can evaluate low-risk entries off recent swing lows, using post-earnings VWAP levels as defined invalidation stops.
GSK announced on Tuesday, November 17, that the U.S. FDA granted accelerated approval to Nelkarmi (neladalkib) for pretreated locally advanced or metastatic ALK-positive non-small cell lung cancer. The approval arrived ten days ahead of the scheduled November 27 PDUFA target date, supported by Phase I/II ALKOVE-1 trial data showing a 49% confirmed overall response rate in alectinib-pretreated patients.
Why it matters
Early regulatory decisions eliminate event binary risk ahead of schedule, providing an immediate fundamental catalyst for GSK while showcasing the commercial pipeline acquired via Nuvalent. The solid 49% response rate in heavily pretreated lung cancer patients strengthens GSK's positioning against peer oncology portfolios. Tactical traders should monitor follow-through volume in GSK shares for evidence of sustained institutional accumulation.
Yesterday we tracked Beren Therapeutics' impending November 17 PDUFA date for Adrabetadex; on Tuesday, the FDA officially approved the therapy—now branded LEMBAZ—for Niemann-Pick disease type C (NPC), marking the first treatment targeting the underlying cholesterol trafficking defect. Phase 3 trial data demonstrated a 55% reduction in mortality risk compared to external controls. Beren also received a valuable Priority Review Voucher (PRV) and announced commercial availability slated for early December.
Why it matters
A first-in-class orphan drug approval featuring a 55% mortality reduction creates long-term commercial exclusivity in a high-unmet-need indication. The issuance of a transferable Priority Review Voucher provides immediate non-dilutive balance sheet flexibility worth roughly $100M+ in market value. Healthcare swing traders should track early December launch metrics and potential PRV monetization updates as fundamental drivers.
Lycia Therapeutics stock surged nearly 4.8% on Wednesday, November 18, after TD Cowen, Jefferies, Guggenheim, and Evercore ISI simultaneously launched coverage with Buy/Outperform ratings. Price targets range from $43 to $75 (Guggenheim high), with analysts highlighting Phase 1 clinical data showing a ~96% reduction in free and total IgE in atopic patients via its proprietary LYTAC protein degradation platform.
Why it matters
A synchronized multi-desk initiation wall from tier-1 firms acts as a major institutional stamp of approval, effectively reversing a prior 8.6% pullback. The wide target deltas ($43-$75) against current market pricing establish clear benchmark goals for institutional allocators. For swing operators, entering on the initiation pivot with a tight stop below the pre-announcement low offers an asymmetric risk-reward setup.
Morgan Stanley upgraded Nucor Corporation (NUE) from Equal-Weight to Overweight on Tuesday, November 17, hiking its price target to $310.00. Analyst Carlos De Alba cited firming near-term domestic steel price forecasts driven by sustained tight supply, falling capital expenditures, and expanding free cash flow generation.
Why it matters
A top-tier sell-side upgrade with an aggressive $310 target provides a clear fundamental trigger for capital rotation out of high-beta tech into cash-generative industrial cyclicals. The combination of declining capex and rising cash flow offers downside protection in a sticky yield environment. Traders can watch for a clean breakout above recent consolidation resistance to confirm multi-week trend continuation.
Salesforce (CRM) shares tumbled 9.41% on Tuesday, November 17, to close at $194.62, marking its sharpest single-day decline since May 2024. The sell-off was driven by software-wide concerns over AI agents displacing seat-based software licensing models, overshadowing Q2 revenue growth of 11% and Agentforce ARR topping $1.5 billion. The sharp move pushed CRM's 14-day RSI down to an oversold 25.74 as spot approaches key multi-month support at $189.50.
Why it matters
The steep drop reflects structural market anxiety regarding software monetization models in an agentic AI era, creating a tactical disconnect against current cash flows. An RSI reading of 25.74 combined with major support at $189.50 frames a classic mean-reversion setup for tactical buyers. A daily hold at $189.50 offers a high-probability bounce entry toward $213.72 resistance, whereas a breakdown opens risk toward $174.41.
Yesterday we covered the initial tech gap-downs following the U.S. Commerce Department's interim restrictions on advanced AI hardware remote access and Chinese data center equipment; however, the regulatory push is now sparking immediate buying interest across domestic optical component leaders. Coherent (COHR), Applied Optoelectronics (AAOI), Lumentum (LITE), and Ciena (CIEN)—which initially sold off on the news—caught bids on expectations of forced domestic equipment sourcing.
Why it matters
Policy-driven supply shifts are creating distinct relative strength momentum setups within the optical transceiver and networking hardware space. As hyperscalers navigate global compliance rules, domestic component suppliers gain immediate pricing power and order visibility. Swing traders can track volume confirmation across names like COHR and LITE as they break out from recent consolidation bases.
Yesterday we covered SPY pinning the 740 Absolute Gamma Level with -$12.9 billion in dealer exposure; today, the index breached that support to close at 732.44, holding its 200-day simple moving average (732.34) by just ten cents after touching an intraday low of 727.00. Options market structure shows net dealer gamma deteriorating further to -$13.65 billion per 1% move, locking the cash index roughly 200 points below the modeled gamma-flip level of 7,541. Total SPY option volume hit $2.5 billion, with puts accounting for 72% ($1.8B) driven by heavy unusual put flow.
Why it matters
Trading directly on top of the 200-day moving average inside a severe negative gamma regime creates extreme intraday volatility where dealer hedging flows amplify every directional push. The failure of Nvidia's strong earnings print to immediately spark an index-level gamma squeeze leaves spot vulnerable to sudden liquidity flushes if the $730-$735 support floor fails. Day traders should watch for opening-drive displacement around 7,42.97 for upside relief or downside acceleration toward the 721-728 zone.
Yesterday we noted the U.S. Dollar Index hitting a 19-month peak of 103.486; on Wednesday, the index advanced further to a fresh high of 103.8 following October retail sales (0.2% MoM) and hawkish Fedspeak. St. Louis Fed President Alberto Musalem stated in Buenos Aires that the economy will likely require several rate hikes before spring 2027 to bring the real fed funds rate to 2.0%-2.5%, while New York Fed President John Williams supported steady tightening toward 4.50%-4.75%.
Why it matters
The dollar's breakout to multi-month highs alongside sticky 10-year Treasury yields near 5.10% tightens broad financial conditions and pressures non-yielding assets, driving gold to 14-month lows ($3,780/oz). Musalem's aggressive multi-hike posture presents direct upside risk to short-end yields, challenging equity market multiples. Active traders must evaluate how this macro yield drag impacts high-duration growth names ahead of today's FOMC minutes.
Hardware Earnings Relief Collides with Negative Index Gamma While Nvidia's blowout $115.8B revenue print and $130B Q4 guide sparked relief across semiconductor supply chains, index futures remain constrained by deep market-maker short-gamma positioning. The lack of a sustained post-earnings index expansion indicates that options market plumbing and hedging flows continue to dictate intraday range boundaries over fundamental beats.
Neocloud Rebounds Highlight High-Beta Sentiment Reversals Extended-hours rallies across leveraged neocloud names like Nebius and CoreWeave show how quickly sentiment can flip when anchor supply commitments jump to $390B. Despite ongoing capacity constraints and capex dilution fears, these high-beta proxies offer outsized swing trade responsiveness to primary hardware prints.
Oncology Binary Readouts Trigger Massive Volume Dislocation Phase 3 clinical trial wins, such as Sellas Life Sciences' AML data and GSK's early FDA approval for Nelkarmi, continue to drive extreme volume turnover and gap-ups in mid-and-small-cap biotechs. These binary events remain isolated from broader macro headwinds, attracting speculative day and swing capital seeking non-correlated returns.
Tier-1 Desk Initiations Provide Fresh Multi-Day Trend Catalysts Synchronized coverage launches from major investment banks—demonstrated by the four-desk initiation wave in Lycia Therapeutics—are acting as powerful capital catalysts. In a choppy macro tape, trading desks are using tier-1 desk ratings and target deltas to establish high-conviction swing entries.
Extreme Breadth Washouts Setup Mean-Reversion Decision Zones With S&P 500 breadth metrics showing only 10% of key stocks in upsloping trends and software names like Salesforce pushing into deeply oversold RSI territory, tactical mean-reversion setups are multiplying. However, with the 10-year Treasury yield sticky and Fed rate hike bets persisting, traders are demanding strict technical confirmation before catching falling knives.
What to Expect
2026-11-18—Release of October FOMC Meeting Minutes
2026-11-19—Anthropic Nasdaq IPO Under Ticker 'ANT' and Intuit Q1 FY27 Earnings Print
2026-11-22—FDA PDUFA Target Action Date for Capricor Therapeutics' Deramiocel
2026-11-25—FDA Target Action Date for Sanofi's Venglustat
How We Built This Briefing
Every story, researched.
Every story verified across multiple sources before publication.
🔍
Scanned
Across multiple search engines and news databases
601
📖
Read in full
Every article opened, read, and evaluated
139
⭐
Published today
Ranked by importance and verified across sources
12
— The Tape Reader
🎙 Listen as a podcast
Subscribe in your favorite podcast app to get each new briefing delivered automatically as audio.
Apple Podcasts
Library tab → ••• menu → Follow a Show by URL → paste